CpG ImmunoPharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Pharmaceuticals; DNA Immunotherapeutics. A particular DNA sequence, cytosine followed by guanine (CpG) common in bacterial and viral DNA and rare in human DNA may produce therapeutic immune responses in humans. CpG ImmunoPharmaceuticals is developing a vaccine for hepatitis B, and a cancer adjuvant. CpG's DNA therapy may be applicable to a wide range of immunological disorders, from asthma to lupus.You may also be interested in...
Hope Springs Eternal in Biopharma IPO Pricing but Bad Haircuts Continue
Biopharma VCs Move to the Middle in 2006
Biopharma IPOs Start Swing Back to Nasdaq
Need a specific report? 1000+ reports available
Buy Reports